Pharma giant Johnson & Johnson is expecting to have a better 2023 performance after reporting strong second-quarter earnings on Wednesday. The company benefited from a well-performing medical devices business that saw significant sales growth in the first part of the year. It also benefited from the increased demand for its cancer medication Darzalex and over-the-counter drugs.
Johnson & Johnson beat the Wall Street estimates in Q2, seeing $2.80 in adjusted earnings per share compared to the $2.62 EPS expected by the analysts. Its revenue came at $25.53 billion versus an estimated $24.62 billion, with a net income of $5.14 billion.
The company now expects to reach between $98.80 billion and $99.80 billion in sales, which represents a $1 billion increase compared to the previous estimate after Q1.
It also raised its earnings prediction to $10.70 to $10.80 per share compared to the $10.60 to $10.70 per share forecast in April. The analysts expected the company to have profits of $10.65 per share for the year.
Johnson & Johnson stock saw a slight movement in pre-market trading on Thursday, at one point reaching $159.30 per share compared to Wednesday’s close of $158.65. The company’s shares have been down almost 11% year-to-date.